Inflammatory profile in cervical cancer: influence of purinergic signaling and possible therapeutic targets
Tóm tắt
Từ khóa
Tài liệu tham khảo
World Health Organization. Cervical cancer [Internet]. [Cited 2021 Dec 31]. Available from: https://www.who.int/health-topics/cervical-cancer#tab=tab_1
Schiffman M, Doorbar J, Wentzensen N, de Sanjosé S, Fakhry C, Monk BJ, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016;2:1–20.
Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynecol Obstet. 2019;145:129–35.
Preci DP, Almeida A, Weiler AL, Mukai Franciosi ML, Cardoso AM. Oxidative damage and antioxidants in cervical cancer. Int J Gynecol Cancer. 2021;31:265–71.
Hemmat N, Bannazadeh BH. Association of human papillomavirus infection and inflammation in cervical cancer. Pathog Dis. 2019;77:1–11.
Pfaffenzeller MS, Franciosi MLM, Cardoso AM. Purinergic signaling and tumor microenvironment in cervical Cancer. Purinergic Signal. 2020;16:123–35.
Sattler C, Benndorf K. Enlightening activation gating in P2X receptors. Purinergic Signal. 2022. https://doi.org/10.1007/s11302-022-09850-w.
Kennedy C. That was then, this is now: the development of our knowledge and understanding of P2 receptor subtypes. Purinergic Signal. 2021;17:9–23.
di Virgilio F, Adinolfi E. Extracellular purines, purinergic receptors and tumor growth. Oncogene. 2017;36:293–303.
Antonioli L, Pacher P, Vizi ES, Haskó G. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2013;19:355–67.
di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S. The P2X7 receptor in infection and inflammation. Immunity. 2017;47:15–31.
Yuan Y, Cai X, Shen F, Ma F. HPV post-infection microenvironment and cervical cancer. Cancer Lett. 2021;497:243–54.
Litwin TR, Irvin SR, Chornock RL, Sahasrabuddhe VV, Stanley M, Wentzensen N. Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis. Br J Cancer. 2021;124:831–41.
Adurthi S, Mukherjee G, Krishnamurthy H, Sudhir K, Bafna UD, Umadevi K, et al. Functional tumor infiltrating TH1 and TH2 effectors in large early-stage cervical cancer are suppressed by regulatory T cells. Int J Gynecol Cancer. 2012;22:1130–7.
Parida S, Mandal M. Inflammation induced by human papillomavirus in cervical cancer and its implication in prevention. Eur J Cancer Prev. 2014;23:432–48.
Nahand JS, Vandchali NR, Darabi H, Doroudian M, Banafshe HR, Moghoofei M, et al. Exosomal microRNAs: novel players in cervical cancer. Epigenomics. 2020;12:1651–60.
Audirac-Chalifour A, Torres-Poveda K, Bahena-Román M, Téllez-Sosa J, Martínez-Barnetche J, Cortina-Ceballos B, et al. Cervical microbiome and cytokine profile at various stages of cervical cancer: a pilot study. PLoS ONE. 2016;11:1–24.
Otani S, Fujii T, Kukimoto I, Yamamoto N, Tsukamoto T, Ichikawa R, et al. Cytokine expression profiles in cervical mucus from patients with cervical cancer and its precursor lesions. Cytokine. 2019;120:210–9.
Liu Y, Li L, Li Y, Zhao X. Research progress on tumor-associated macrophages and inflammation in cervical cancer. Biomed Res Int. 2020;2020:1–6.
Guo N, Shen G, Zhang Y, Moustafa AA, Ge D, You Z. Interleukin-17 promotes migration and invasion of human cancer cells through upregulation of MTA1 expression. Front Oncol. 2019;9:1–11.
Wu L, Chen X, Zhao J, Martin B, Zepp JA, Ko JS, et al. A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4–ERK5 axis. J Exp Med. 2015;212:1571–87.
Liu Y, Guo Q-F, Chen J-L, Li X-R, Hou F, Liu X-Y, et al. Correlations between alterations of T-helper 17 cells and treatment efficacy after concurrent radiochemotherapy in locally advanced cervical cancer (stage IIB–IIIB): a 3-year prospective study. Chin Med J. 2021;134:954–62.
Zhang W, Tian X, Mumtahana F, Jiao J, Zhang T, Croce KD, et al. The existence of Th22, pure Th17 and Th1 cells in CIN and cervical cancer along with their frequency variation in different stages of cervical cancer. BMC Cancer. 2015;15:1–11.
Alves J, Fernandes T, de Araújo J, Cobucci R, Lanza D, Bezerra F, et al. Th17 response in patients with cervical cancer (Review). Oncol Lett. 2018;16:6215–27.
Xue J, Wang Y, Chen C, Zhu X, Zhu H, Hu Y. Effects of Th17 cells and IL-17 in the progression of cervical carcinogenesis with high-risk human papillomavirus infection. Cancer Med. 2018;7:297–306.
Zhang Y, Ma D, Zhang Y, Tian Y, Wang X, Qiao Y, et al. The imbalance of Th17/Treg in patients with uterine cervical cancer. Clin Chim Acta. 2011;412:894–900.
Artaza-Irigaray C, Molina-Pineda A, Aguilar-Lemarroy A, Ortiz-Lazareno P, Limón-Toledo LP, Pereira-Suárez AL, et al. E6/E7 and E6* from HPV16 and HPV18 upregulate IL-6 expression independently of p53 in keratinocytes. Front Immunol. 2019;10:1–11.
Vitkauskaite A, Urboniene D, Celiesiute J, Jariene K, Skrodeniene E, Nadisauskiene RJ, et al. Circulating inflammatory markers in cervical cancer patients and healthy controls. J Immunotoxicol. 2020;17:105–9.
Esmailbeig M, Ghaderi A. Interleukin-18: a regulator of cancer and autoimmune diseases. Eur Cytokine Netw. 2017;28:127–40.
Lu Z, Zhu M, Marley JL, Bi K, Wang K, Zhai M, et al. The combined action of monocytic myeloid-derived suppressor cells and mucosal-associated invariant T cells promotes the progression of cervical cancer. Int J Cancer. 2021;148:1499–507.
Maldonado PA, Pimentel VC, Negrini LA, Morsch VM, Schetinger MRC. Role of the purinergic system in patients with cervical intraepithelial neoplasia and uterine cancer. Biomed Pharmacother. 2012;66:6–11.
di Virgilio F, Sarti AC, Falzoni S, de Marchi E, Adinolfi E. Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat Rev Cancer. 2018;18:601–18.
Grassi F. The P2X7 receptor as regulator of T cell development and function. Front Immunol. 2020. https://doi.org/10.3389/fimmu.2020.01179.
Muscella A, Elia MG, Greco S, Storelli C, Marsigliante S. Activation of P2Y2 purinoceptor inhibits the activity of the Na+/K+-ATPase in HeLa cells. Cell Signal. 2003;15:115–21.
Durlacher CT, Chow K, Chen X-W, He Z-X, Zhang X, Yang T, et al. Targeting Na+/K+-translocating adenosine triphosphatase in cancer treatment. Clin Exp Pharmacol Physiol. 2015;42:427–43.
Muscella A, Elia MG, Greco S, Storelli C, Marsigliante S. Activation of P2Y2 receptor induces c-FOS protein through a pathway involving mitogen-activated protein kinases and phosphoinositide 3-kinases in HeLa cells. J Cell Physiol. 2003;195:234–40.
Gendaszewska-Darmach E, Szustak M. Thymidine 5’-O-monophosphorothioate induces HeLa cell migration by activation of the P2Y6 receptor. Purinergic Signal. 2016;12:199–209.
Swanson KV, Deng M, Ting JP-Y. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19:477–89.
Piccini A, Carta S, Tassi S, Lasiglie D, Fossati G, Rubartelli A. ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1 and IL-18 secretion in an autocrine way. Proc Natl Acad Sci. 2008;105:8067–72.
Savio LEB, de Andrade MP, da Silva CG, Coutinho-Silva R. The P2X7 receptor in inflammatory diseases: angel or demon? Front Pharmacol. 2018;9:1–31.
Sharma S, Kalra H, Akundi RS. Extracellular ATP mediates cancer cell migration and invasion through increased expression of cyclooxygenase 2. Front Pharmacol. 2021;11:1–18.
Bae JY, Lee S-W, Shin Y-H, Lee J-H, Jahng JW, Park K. P2X7 receptor and NLRP3 inflammasome activation in head and neck cancer. Oncotarget. 2017;8:48972–82.
Feng Y-H, Li X, Wang L, Zhou L, Gorodeski GI. A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through hetero-oligomerization. J Biol Chem. 2006;281:17228–37.
Wang B, Wang H, Li P, Wang L, Liu H, Liu J, et al. Relationships of interleukin-10 with the regulatory T cell ratio and prognosis of cervical cancer patients. Clinics. 2018;73:1–5.
Feng Q, Wei H, Morihara J, Stern J, Yu M, Kiviat N, et al. Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma. Gynecol Oncol. 2012;127:412–9.
Sek K, Mølck C, Stewart G, Kats L, Darcy P, Beavis P. Targeting adenosine receptor signaling in cancer immunotherapy. Int J Mol Sci. 2018;19:1–23.
De Mello AP, Filippi-Chiela EC, Nascimento J, Beckenkamp A, Santana DB, Kipper F, et al. Adenosine uptake is the major effector of extracellular ATP toxicity in human cervical cancer cells. Mol Biol Cell. 2014;25:2905–18.
de Lourdes M-G, García-Rocha R, Morales-Ramírez O, Montesinos JJ, Weiss-Steider B, Hernández-Montes J, et al. Mesenchymal stromal cells derived from cervical cancer produce high amounts of adenosine to suppress cytotoxic T lymphocyte functions. J Transl Med. 2016;14:1–14.
de Marchi E, Orioli E, Pegoraro A, Sangaletti S, Portararo P, Curti A, et al. The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment. Oncogene. 2019;38:3636–50.